paper_id,claim,figure_id,title,caption,local_image_path,url
PMC10687901,A flow-chart detailing all exclusions is available in Fig. 1.,PMC10687901_figure_1,Fig. 1.,"Flow-chart for trial inclusion. ICTRP, International Clinical Trials Registry Platform. Cross-registrations include those identified in automated and manual screening of registries and publications",./data/PMC10687901/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5371/10687901/621f59198711/12916_2023_3161_Fig1_HTML.jpg
PMC10687901,"Figure 4 shows the delay from preprint to full journal publication for all preprints; journal articles published prior to preprints were set to time 0, and preprints without a journal publication were censored at the start of result searches.",PMC10687901_figure_4,Fig. 4.,Time from preprint to journal publication,./data/PMC10687901/images/figure_4.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5371/10687901/d80ba617a797/12916_2023_3161_Fig4_HTML.jpg
PMC10687901,"Subgroup analyses
Figure 5a shows time to reporting stratified by whether trials completed in the early, middle, or late periods of the first 18 months of the COVID-19 pandemic.",PMC10687901_figure_5,Fig. 5.,A–C Time to dissemination by subgroups. A 6-month phase of the pandemic. B Top 5 common interventions. C Based on trial design standards. HCQ: Hydroxychloroquine; Con. Plasma: Convalescent Plasma,./data/PMC10687901/images/figure_5.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5371/10687901/13f4d929a798/12916_2023_3161_Fig5_HTML.jpg
PMC10687901,Figure 5b shows how this compares to trials without these characteristics.,PMC10687901_figure_5,Fig. 5.,A–C Time to dissemination by subgroups. A 6-month phase of the pandemic. B Top 5 common interventions. C Based on trial design standards. HCQ: Hydroxychloroquine; Con. Plasma: Convalescent Plasma,./data/PMC10687901/images/figure_5.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5371/10687901/13f4d929a798/12916_2023_3161_Fig5_HTML.jpg
PMC10687901,"Figure 5a shows time to reporting stratified by whether trials completed in the early, middle, or late periods of the first 18 months of the COVID-19 pandemic.",PMC10687901_figure_5,Fig. 5.,A–C Time to dissemination by subgroups. A 6-month phase of the pandemic. B Top 5 common interventions. C Based on trial design standards. HCQ: Hydroxychloroquine; Con. Plasma: Convalescent Plasma,./data/PMC10687901/images/figure_5.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5371/10687901/13f4d929a798/12916_2023_3161_Fig5_HTML.jpg
